002007 华兰生物
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,652,7074.26%5,341,8734,516,9794,436,2005,023,206
减:营业总成本1,256,23014.42%3,424,9913,113,1932,715,2062,939,045
    其中:营业成本814,92927.48%1,624,4781,532,8651,386,8801,371,236
               财务费用(8,264)12,236.91%(1,672)9,6799,809(10,913)
               资产减值损失----(90,879)(157,297)(133,252)(33,625)
公允价值变动收益19,356-45.20%60,54436,10726,85925,964
投资收益67,879-9.19%149,046107,94673,36384,770
    其中:对联营企业和合营企业的投资收益(13,450)-12.30%(25,645)(26,407)(13,932)5,222
营业利润538,958-22.84%2,098,3901,424,4631,696,4162,150,501
利润总额533,917-22.38%2,077,6431,428,3681,688,2452,147,377
减:所得税费用85,142-32.30%315,958180,765234,128303,213
净利润448,775-20.16%1,761,6851,247,6031,454,1171,844,164
减:非控股权益8,579-75.80%280,106171,338155,220231,059
股东净利润440,196-16.42%1,481,5791,076,2651,298,8971,613,105

市场价值指针
每股收益 (元) *0.241-16.66%0.8120.5900.7130.887
每股派息 (元) *----0.3000.3000.2000.300
每股净资产 (元) *6.1528.04%6.2115.7004.5704.127
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容